Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

May 2023| BIO074D| BCC Publishing
Sample Report

Report Highlights

The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.

Report Includes

  • 43 tables
  • An overview of the global market and technologies for central nervous system (CNS) biomarkers
  • Estimation of the market size and analyses of market trends, with data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Explanation of market drivers, restraints and other forces impacting the global market
  • Description of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
  • Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others
  • Coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Comprehensive company profiles of major players of the industry, including Abbott, Bio-Rad Laboratories Inc., Eisai Co. Ltd., Merck and Thermo Fisher Scientific Inc.

Report Scope

This study provides a comprehensive analysis of CNS biomarkers on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the global CNS biomarkers market.

Current and projected product forecasts during the forecast period (2022 to 2027) are discussed. New products approved in 2021 and 2022 by the U.S. Food and Drug Administration (FDA), and those products expected to be approved within the forecast period are discussed. Market figures for 2022 are estimated, except where actual results have been reported.

Included in this report are forecasts by biomarker type, technology type, disease, application, and region from 2022 through 2027. The report also includes analysis of leading and emerging competitors in the current worldwide CNS biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define the specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care.

Frequently Asked Questions (FAQs)

The global CNS biomarker market was valued at $5.7 billion in 2022. The market is projected to reach $9.5 billion in 2027, growing at a CAGR of 10.8% during the forecast period.
This aggressive growth rate is driven by several factors, including the increase in public-private partnerships with government support, pressure to keep healthcare costs down, a growing elderly population and the rapid advancement of genomic and proteomic technologies which have impacted the CNS biomarker diagnostics area. There is huge unmet need in the area of CNS diseases due to the lack of fast and sensitive diagnostic methods and effective treatments. CNS biomarkers are rapidly emerging as the mainstay in the identification of patients at risk, early diagnosis, follow-up of disease progression, and effectiveness of treatments in neurology, in particular for demyelinating diseases (such as multiple sclerosis), neurodegenerative diseases (such as Alzheimer’s disease) or traumatic brain injury.
An in-depth analysis of the global CNS biomarkers market, including historical data and market projection on sales by type, technology, application, disease, and region.
All other CNS biomarkers segment is expected to dominate the market by the end of 2027.
North America has the highest market share in the CNS biomarkers market.
F. Hoffmann-La Roche AG, ThermoFisher Scientific, Merck KGaA, Siemens Healthineers, Eli Lilly and Co., PerkinElmer, Labcorp., bioMérieux, Shimadzu Corp., Fujirebio, Sysmex Corp., Abbott Laboratories, C2N Diagnostics, Bio-Rad Laboratories, Inc.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2021
Forecast period considered 2022-2027
Base year market size $5.2 billion
Market size forecast $9.5 billion
Growth rate CAGR of 10.8%
Units considered $ Millions
Segments covered Disease, Application, Technology, Biomarker Type,
Regions covered North America, Europe, Asia-Pacific, and ROW
Countries covered United States, Canada, Germany, France, United Kingdom, Italy, Rest of Europe, China, India, Japan, Rest of Asia-Pacific, Latin America, Middle East and Africa
Key Market Drivers
  • Growing Incidence and Financial Burden of Neurological Disorders
  • High Unmet Need in Neurodegenerative Disorders
  • Need to Reduce Drug Development Costs and Failures
  • Increasing investment in Neuroscience
  • Developments in Analytical Technologies and Assay Methods
  • Support from Regulatory Agencies
Companies studied
  • ABBOTT LABORATORIES LTD.
  • BIOMERIEUX S.A.
  • BIO-RAD LABORATORIES, INC.
  • C₂N DIAGNOSTICS, LLC
  • DIADEM SPA
  • Eisai Co., Ltd.
  • ELI LILLY AND CO.
  • F. HOFFMANN-LA ROCHE AG
  • H.U. GROUP HOLDINGS INC.
  • LABORATORY CORP. OF AMERICA (LABCORP)
  • MERCK KGAA
  • PERKINELMER INC.
  • QUANTERIX CORP.
  • QUEST DIAGNOSTICS INC.
  • SHIMADZU CORP.
  • SIEMENS HEALTHINEERS AG
  • SYSMEX CORP.
  • THERMO FISHER SCIENTIFIC INC.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
. Title/Chapter NamePagesPrice Member Price
Full Report: Central Nervous System (CNS) Biomarkers: Technologies and Global Markets135 $5,500 Free
Chapter- 1: Introduction8Free DownloadFree
Chapter- 2: Summary and Highlights2$250Free
Chapter- 3: Market and Technology Background5$204Free
Chapter- 4: Market Dynamics10$407Free
Chapter- 5: Market Breakdown by Disease21$856Free
Chapter- 6: Market Breakdown by Application15$611Free
Chapter- 7: Market Breakdown by Technology Type12$489Free
Chapter- 8: Market Breakdown by Biomarker Type8$326Free
Chapter- 9: Market Breakdown by Region13$530Free
Chapter- 10: Impact of COVID-192$81Free
Chapter- 11: Competitive Landscape7$285Free
Chapter- 12: Emerging Products/Technologies in the Market5$204Free
Chapter- 13: Company Profiles27$1,100Free
Published - Mar-2016| Analyst - Jackson Highsmith| Code - BIO074C

Report Highlights

The global CNS biomarker market is projected to reach $5.1 billion by 2020 from $3.1 billion in 2015, at a compound annual growth rate (CAGR) of 10.4%.

Report Includes

  • An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
  • Analyses of global market trends, with data from 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2020.
  • Evaluation of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
  • Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
  • Patent analyses.
  • Profiles of major players in the field.
Published - Mar-2013| Analyst - Jackson Highsmith| Code - BIO074B

Report Highlights

The global CNS biomarker market was estimated at $1.7 billion in 2011 and nearly $2 billion in 2012. The market is projected to reach $5.1 billion by the end of the forecast period of 2012 to 2017, representing a compound annual growth rate (CAGR) of 20.7%.

Report Includes

  • An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
  • Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.
  • Evaluations of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
  • Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
  • Patent analyses.
  • Comprehensive company profiles of major players.
Published - Oct-2010| Analyst - Munish Das| Code - BIO074A

Report Highlights

  • The global CNS biomarker market was estimated at $1.3 billion in 2009 and is expected to reach close to $3.2 billion by 2015, with a compound annual growth rate (CAGR) of 17.1% from 2010 to 2015.
  • The CNS molecular diagnostic market will see the largest growth, with a compound annual growth rate (CAGR) of 172.3% from 2010 to 2015 due to the number of diagnostic tests that are in the pipeline. This sector is valued at $2 million in 2010 and is expected to be worth $302 million in 2015.
  • The growth rate for the CNS biomarker market for drug development will increase as more validated biomarkers become available for patient segmentation and assessment of efficacy for clinical trials. This sector is worth an estimated $162 million in 2010 and is expected to reach $355 million in 2015, a 17% compound annual growth rate (CAGR).
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS